Floatz logo

Solvazinc

Myofacial Pain Syndrome

Cairo UniversityEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Myofacial Pain Syndrome cohort.

Asset / SponsorPhaseRating
Granisetron
Karolinska Institutet
Phase 4BB
Imc-1
Innovative Med Concepts, LLC
Phase 2B
Capsaicin
Stamford Hospital
Phase 2CCC
BICARBONATE ION
Cairo University
N/AD
DEXTROSE
Ankara University
D

View all 12 →

Same molecule, other indications

Solvazinc is also rated in:

Botulinum ToxinDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →